NASDAQ:INCY - Incyte Stock Price, News & Analysis

$81.91
-3.65 (-4.27 %)
(As of 08/25/2019 07:49 AM ET)
Today's Range
$81.61
Now: $81.91
$85.82
50-Day Range
$78.69
MA: $82.20
$85.83
52-Week Range
$57.00
Now: $81.91
$89.30
Volume853,755 shs
Average Volume1.16 million shs
Market Capitalization$17.62 billion
P/E Ratio54.15
Dividend YieldN/A
Beta1.12
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.88 billion
Cash Flow$1.0433 per share
Book Value$10.45 per share

Profitability

Net Income$109.49 million

Miscellaneous

Employees1,367
Market Cap$17.62 billion
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.


Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, July, 30th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.38 by $0.37. The biopharmaceutical company had revenue of $529.93 million for the quarter, compared to analysts' expectations of $498.57 million. Incyte had a net margin of 15.25% and a return on equity of 17.10%. The business's quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. View Incyte's Earnings History.

When is Incyte's next earnings date?

Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Incyte.

What price target have analysts set for INCY?

21 Wall Street analysts have issued twelve-month price targets for Incyte's shares. Their forecasts range from $74.00 to $111.00. On average, they expect Incyte's stock price to reach $90.0588 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for Incyte.

What is the consensus analysts' recommendation for Incyte?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.

What are Wall Street analysts saying about Incyte stock?

Here are some recent quotes from research analysts about Incyte stock:
  • 1. According to Zacks Investment Research, "Incyte’s lead drug, Jakafi continues to maintain momentum for the company, as the underlying patient demand for the drug remains strong for both MF and PV. Incyte is working to expand the drug’s label into additional indications which should further boost sales. The FDA approval of Olumiant 2 mg, for which the company received a milestone payment from Lilly, is a positive. Shares have outperformed the industry in the past six months. However, pipeline setbacks continue to be a concern. The FDA’s extension of the review period of the sNDA for the label expansion of Jakafi to treat acute GVHD was disappointing.  Earlier, Incyte suffered a setback with the failure of the phase III ECHO-301 study, evaluating epacadostat in combination with Keytruda." (4/29/2019)
  • 2. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018)
  • 3. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018)

Has Incyte been receiving favorable news coverage?

News coverage about INCY stock has been trending positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Incyte earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Incyte.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Who are Incyte's key executives?

Incyte's management team includes the folowing people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.04%), BlackRock Inc. (6.95%), BlackRock Inc. (6.95%), Price T Rowe Associates Inc. MD (3.56%), Invesco Ltd. (2.42%) and UBS Asset Management Americas Inc. (1.86%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar and Yao Wenqing. View Institutional Ownership Trends for Incyte.

Which major investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, BlackRock Inc., BlackRock Inc., JPMorgan Chase & Co., Pictet Asset Management Ltd., Banco Santander S.A., Russell Investments Group Ltd. and Allianz Asset Management GmbH. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein and Yao Wenqing. View Insider Buying and Selling for Incyte.

Which major investors are buying Incyte stock?

INCY stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, Renaissance Technologies LLC, Bessemer Group Inc., Vanguard Group Inc., First Trust Advisors LP, Bank of New York Mellon Corp and Marshall Wace North America L.P.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $81.91.

How big of a company is Incyte?

Incyte has a market capitalization of $17.62 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe.View Additional Information About Incyte.

What is Incyte's official website?

The official website for Incyte is http://www.incyte.com/.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


MarketBeat Community Rating for Incyte (NASDAQ INCY)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  1,042 (Vote Outperform)
Underperform Votes:  554 (Vote Underperform)
Total Votes:  1,596
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel